Cargando…

(18)F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging

INTRODUCTION: The fibroblast growth factor receptor (FGFR) family is highly expressed in a variety of tumor types and represents a new target for cancer therapy. Different FGFR subtype aberrations have been found to exhibit highly variable sensitivity and efficacy to FGFR inhibitors. METHODS: The pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yang, Han, Jingya, Zhao, Yan, Zhao, Xinming, Zhao, Mengmeng, Zhang, Jingmian, Wang, Jianfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174317/ https://www.ncbi.nlm.nih.gov/pubmed/37182162 http://dx.doi.org/10.3389/fonc.2023.1047080

Ejemplares similares

Pre-Clinical Study of the [(18)F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer
por: Han, Jingya, et al.
Publicado: (2022)

Case Report: (68)Ga-FAPI PET/CT, a more advantageous detection mean of gastric, peritoneal, and ovarian metastases from breast cancer
por: Li, Tianyue, et al.
Publicado: (2022)

Predicting PD-L1 expression status in patients with non-small cell lung cancer using [(18)F]FDG PET/CT radiomics
por: Zhao, Xiaoqian, et al.
Publicado: (2023)

Value of pre-treatment (18)F-FDG PET/CT radiomics in predicting the prognosis of stage III-IV colorectal cancer
por: Wang, Na, et al.
Publicado: (2023)

Baseline (18)F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma
por: Jing, Fenglian, et al.
Publicado: (2023)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

(18)F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis
por: Jiang, Yuchen, et al.
Publicado: (2022)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas
por: Egbivwie, Naomi, et al.
Publicado: (2019)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Case Report: A novel FGFR1 fusion in acute B-lymphoblastic leukemia identified by RNA sequencing
por: Zhang, Zhibo, et al.
Publicado: (2023)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Myeloid/Lymphoid Neoplasm With FGFR1 Rearrangement Accompanying RUNX1 and NOTCH1 Gene Mutations
por: Wang, Xiaoxue, et al.
Publicado: (2019)

Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer
por: Yang, Chengcheng, et al.
Publicado: (2022)

FGFR1 expression defines clinically distinct subtypes in pancreatic cancer
por: Haq, Farhan, et al.
Publicado: (2018)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Peptide-based NTA(Ni)-nanodiscs for studying membrane enhanced FGFR1 kinase activities
por: Liu, Juanjuan, et al.
Publicado: (2019)

Novel FGFR1 Variants Are Associated with Congenital Scoliosis
por: Wang, Shengru, et al.
Publicado: (2021)

Convenient Preparation of (18)F-Labeled Peptide Probes for Potential Claudin-4 PET Imaging
por: Feni, Lucia, et al.
Publicado: (2017)

Fetal microtia and FGFR2 polymorphism
por: Zhao, Ruilian, et al.
Publicado: (2019)

FGFR2/STAT3 Signaling Pathway Involves in the Development of MMTV-Related Spontaneous Breast Cancer in TA2 Mice
por: Du, Jiaxing, et al.
Publicado: (2020)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Role of Postnatal Expression of Fgfr1 and Fgfr2 in Testicular Germ Cells on Spermatogenesis and Fertility in Mice
por: Li, Shengqiang, et al.
Publicado: (2014)

[18F]FDG PET/CT versus [18F]FDG PET/MRI for the diagnosis of colorectal liver metastasis: A systematic review and meta-analysis
por: Miao, Zhi, et al.
Publicado: (2023)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

MicroRNA-99a Suppresses Breast Cancer Progression by Targeting FGFR3
por: Long, Xinghua, et al.
Publicado: (2020)

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
por: Kitowska, Kamila, et al.
Publicado: (2021)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p4m1k40lo9pkmmtkftc5il8u0q